drugset / Trial / NCT01579578

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

NCT01579578

Phase 2 Terminated 39 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to assess the efficacy and safety and PK of AZD8931 plus paclitaxel versus paclitaxel alone in patients with metastatic, gastric or gastro-oesophageal junction, cancer.

Timeline

Start
2012-04
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SAPITINIB Small molecule 40 mg Oral
Background Paclitaxel Small molecule Intravenous